Ace Neuroscience Unveils Integrated Drug Development Services for Stroke

Ace Neuroscience announces the launch of its integrated drug development services specifically designed for preclinical research on stroke.
New York, USA - April 15, 2024 - Ace Neuroscience, a preclinical CRO service provider engaged in the research of stroke and antipsychotic drug development, announces the launch of its integrated drug development services specifically designed for preclinical research on stroke. With a dedicated team of experts and extensive expertise, Ace Neuroscience aims to accelerate the stroke research process, help scholars to complete their research projects faster and more successfully, and find a cure for stroke sooner.

Stroke is considered the third leading cause of death and a significant cause of long-term disability and cognitive impairment. Although research into stroke has been ongoing for decades, reperfusion with recombinant tissue plasminogen activator (rtPA) remains the only FDA-approved drug for treating stroke. Therefore, it is urgent to accelerate the understanding of the injury mechanisms of stroke and to facilitate the development of new therapies for stroke.

Ace Neuroscience [https://www.advaneuro.com/], as a biological company specializing in pre-clinical CRO services for stroke, provides a wide range of drug development services for stroke, such as small molecule drug development and biological therapy development. Its team of professionals will conduct drug screening, drug efficacy testing, pharmacokinetic testing, safety evaluation testing, and pharmaceutic preparations for clients. By combining cutting-edge research, innovative technology, and strategic partnerships, Ace Neuroscience's stroke drug development services feature:

- Innovative biological therapy development including stem cell therapy, antibody therapy, and exosome-based therapy

- Creative drug development strategies targeting cell death and other cell types

- Large small molecule libraries to allow different drug screening approaches

- Advanced animal models and cutting-edge imaging techniques available

- Translation of promising drug candidates into clinical trials

Ace Neuroscience's integrated stroke drug development services [https://www.advaneuro.com/drug-development-for-stroke.html] are flexible and can be tailored for pharmaceutical companies, research institutions, and academic organizations seeking to speed up the development of new therapies for both ischemic and hemorrhagic stroke. With the commitment to accelerating progress in stroke research and drug development, Ace Neuroscience is a trustworthy CRO in this cause.

About Ace Neuroscience

Ace Neuroscience is committed to supporting researchers in making groundbreaking scientific discoveries and developing new applications to accelerate stroke research as well as antipsychotic drug development [https://www.advaneuro.com/antipsychotics/]. Over the years, the company has collaborated with many pharmaceutical and biotechnology companies by offering comprehensive basic research services and drug development solutions to help researchers avoid potential hurdles and facilitate their endeavors.
Media Contact
Company Name: Ace Neuroscience
Contact Person: Daisy Mostert
Email: Send Email [http://www.universalpressrelease.com/?pr=ace-neuroscience-unveils-integrated-drug-development-services-for-stroke]
Phone: 1-516-441-0167
Country: United States
Website: https://www.advaneuro.com



This release was published on openPR.